Literature DB >> 29666482

Letter to the Editor.

Yuan Zhang1,2, Yuanzhi Yuan3,4.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29666482      PMCID： PMC6085339          DOI： 10.1038/s41433-018-0090-7

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

Review 1.  Quasi-experimental designs.

Authors:  G A Morgan; J A Gliner; R J Harmon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-06       Impact factor: 8.829

2.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.

Authors:  Gilda Piaggio; Diana R Elbourne; Douglas G Altman; Stuart J Pocock; Stephen J W Evans
Journal:  JAMA       Date:  2006-03-08       Impact factor: 56.272

3.  Case-control studies: basic concepts.

Authors:  Jan P Vandenbroucke; Neil Pearce
Journal:  Int J Epidemiol       Date:  2012-10       Impact factor: 7.196

4.  Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.

Authors:  Donald S Fong; Peter Custis; Jennifer Howes; Jin-Wen Hsu
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

5.  Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study.

Authors:  J Cui; D Sun; H Lu; R Dai; L Xing; H Dong; L Wang; D Wei; B Jiang; Y Jiao; M M Jablonski; S Charles; W Gu; H Chen
Journal:  Eye (Lond)       Date:  2017-09-22       Impact factor: 3.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.